Cue Biopharma (CUE) Set to Announce Quarterly Earnings on Monday

Cue Biopharma (NASDAQ:CUE) is scheduled to be announcing its earnings results on Monday, April 8th.

Cue Biopharma Stock Up 3.9 %

Shares of NASDAQ CUE opened at $1.85 on Friday. Cue Biopharma has a one year low of $1.70 and a one year high of $5.12. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.34 and a quick ratio of 3.34. The business’s fifty day moving average price is $2.11 and its 200-day moving average price is $2.35. The stock has a market capitalization of $89.99 million, a PE ratio of -1.55 and a beta of 2.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Cue Biopharma by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 2,132,905 shares of the company’s stock valued at $5,631,000 after purchasing an additional 7,999 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Cue Biopharma by 205.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 58,324 shares of the company’s stock valued at $154,000 after purchasing an additional 39,211 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Cue Biopharma in the 4th quarter valued at approximately $37,000. Barclays PLC increased its position in Cue Biopharma by 362.2% during the 4th quarter. Barclays PLC now owns 55,529 shares of the company’s stock valued at $146,000 after buying an additional 43,516 shares in the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in Cue Biopharma during the 4th quarter valued at approximately $88,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CUE shares. Jefferies Financial Group started coverage on Cue Biopharma in a research report on Wednesday, March 13th. They set a “buy” rating and a $6.00 price objective on the stock. Piper Sandler reiterated an “overweight” rating and set a $8.00 price objective on shares of Cue Biopharma in a research report on Wednesday.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.